Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2020 1
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity.
Rogdakis T, Charou D, Latorrata A, Papadimitriou E, Tsengenes A, Athanasiou C, Papadopoulou M, Chalikiopoulou C, Katsila T, Ramos I, Prousis KC, Wade RC, Sidiropoulou K, Calogeropoulou T, Gravanis A, Charalampopoulos I. Rogdakis T, et al. Among authors: chalikiopoulou c. Biomedicines. 2022 Mar 6;10(3):614. doi: 10.3390/biomedicines10030614. Biomedicines. 2022. PMID: 35327415 Free PMC article.
The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review.
Kumuthini J, Zick B, Balasopoulou A, Chalikiopoulou C, Dandara C, El-Kamah G, Findley L, Katsila T, Li R, Maceda EB, Monye H, Rada G, Thong MK, Wanigasekera T, Kennel H, Marimuthu V; G2MC Evidence investigators, Williams MS, Al-Mulla F, Abramowicz M. Kumuthini J, et al. Among authors: chalikiopoulou c. Hum Genet. 2022 Apr 30:1-8. doi: 10.1007/s00439-022-02452-x. Online ahead of print. Hum Genet. 2022. PMID: 35488921 Free PMC article. Review.
A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients with Different Clinical Outcomes.
Bafiti V, Ouzounis S, Chalikiopoulou C, Grigorakou E, Grypari IM, Gregoriou G, Theofanopoulos A, Panagiotopoulos V, Prodromidi E, Cavouras D, Zolota V, Kardamakis D, Katsila T. Bafiti V, et al. Among authors: chalikiopoulou c. Curr Oncol. 2022 Jun 16;29(6):4315-4331. doi: 10.3390/curroncol29060345. Curr Oncol. 2022. PMID: 35735454 Free PMC article.
Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
Chalikiopoulou C, Tavianatou AG, Sgourou A, Kourakli A, Kelepouri D, Chrysanthakopoulou M, Kanelaki VK, Mourdoukoutas E, Siamoglou S, John A, Symeonidis A, Ali BR, Katsila T, Papachatzopoulou A, Patrinos GP. Chalikiopoulou C, et al. Pharmacogenomics. 2016 Mar;17(4):393-403. doi: 10.2217/pgs.16.1. Epub 2016 Feb 19. Pharmacogenomics. 2016. PMID: 26895070